Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: Reliability of different sampling models

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 2, 2008, Pages 491-496

  Studen, Katica Bajuk ^a   Barkan, Ariel ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ACROMEGALY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 39049119858     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1451     Document Type: Article

References (28)

1. Melmed S 2006 Medical progress: acromegaly. N Engl J Med 355:2558-2573
2. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A, Acromegaly Treatment Consensus Workshop Participants 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
3. Clemmons DR 2006 Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2:436-446
4. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL 2002 Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537-3542
5. Barkan AL, Beitins IZ, Kelch RP 1988 Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 67:69-73
6. Hartman ML, Veldhuis JD, Vance ML, Faria AC, Furlanetto RW, Thorner MO 1990 Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab 70:1375-1384
7. Stewart PM 2000 Current therapy for acromegaly. Trends Endocrinol Metab 11:128-132
8. Sheppard MC 2005 GH and mortality in acromegaly. J Endocrinol Invest 28(Suppl 11):75-77
9. Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R, Angeletti G 2005 Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. J Endocrinol Invest 28:978-983
10. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G 2006 Primary treatment of acromegaly with octreotide LAR: a long term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-1403
11. Conceicao FL, Fisker S, Christiansen JS, Astrup J, Weeke J, Jorgensen JO 2003 Biochemical definitions of disease activity in acromegaly. Growth Horm IGF Res 13:98-103
12. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF 2003 Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567-3572
13. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ 1988 Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. J Clin Endocrinol Metab 66:16-23
14. Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkan AL 1994 Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 78:1403-1409
15. Newcombe RG 1998 Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17:857-872
16. Altman DG, Bland JM 1983 Measurement in medicine: the analysis of method comparison studies. Statistician 32:307-317
17. Bercu BB, Shulman D, Root AW, Spiliotis BE 1986 Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion. J Clin Endocrinol Metab 63:709-716
18. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO 1987 Effects of sex and age on the 24-k profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64:51-58
19. Holdaway IM, Rajasoorya C 1999 Epidemiology of acromegaly. Pituitary 2:29-41
20. Holdaway IM, Rajasoorya CR, Gamble GD, AW Stewart 2003 Long term treatment outcome in acromegaly. Growth Horm IGF Res 13:185-192
21. Ho PJ, Friberg RD, Barkan AL 1992 Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly. J Clin Endocrinol Metab 75:812-819
22. Swearingen B, Barker 2nd FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black P, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
23. Beauregard C, Truong U, Hardy J, Serri O 2003 Long term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91
24. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F 2004 Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor 1 measurements. J Clin Endocrinol Metab 89:2789-2796
25. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
26. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E 2005 A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-4086
27. Taboada GF, Correa LL, de Oliveira Machado E, van Haute FR, Casini AF, Balarini GA, Neto LV, Calixto L, Calixto C, Gadelha MR 2007 Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR. Growth Horm IGF Res 17:77-81
28. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB 2001 Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86:1645-1652